GHO Capital Partners LLP has acquired DNA Diagnostics Center from MTS Health Investors LLC for $110 million.

DNA Diagnostics provides private DNA testing services, including paternity tests, veterinary services, forensic services and cell-line authentication for the pharmaceutical industry.

New York private equity firm MTS invested in DNA Diagnostics in 2008. The firm focuses on health care companies, and is invested in care-management service MyNexus, health care information-management group Trust Healthcare Consulting Services LLC and reproductive technology business Ovagen Fertility.

London-based GHO also focuses just on health care companies – especially those in targeted sub-sectors. GHO was founded in 2014, and DNA Diagnostics is its only current portfolio company.

Robert W. Baird & Co. was DNA Diagnostics' financial adviser and Hogan Lovells provided legal advice. 

The deal comes at a busy time in the health care sector, M&A-wise. Part of the sector-wide deal spree is driven by the Affordable Care Act, as health care providers ramp up technology and combined services to save money as they try to improve patient outcomes.

Recent health care deals include Roche Holding AG's (VTS: ROG) deal for Adheron Therapeutics, and Compassus' acquisition of Hospice Advantage

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.